Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Besifloxacin - Bausch and Lomb

Drug Profile

Besifloxacin - Bausch and Lomb

Alternative Names: Besifloxacin ophthalmic suspension 0.6%; Besivance; BOL-303224-A; ISV-403; Optura; SS 734

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InSite Vision; SSP Co
  • Developer Bausch & Lomb; Rutgers
  • Class Antibacterials; Azepines; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Infectious conjunctivitis
  • No development reported Eye disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Eye-disorders(In infants) in USA (Ophthalmic, Suspension)
  • 03 Nov 2015 InSite Vision became an indirect wholly owned subsidiary of Sun Pharma
  • 04 Feb 2015 Launched for Infectious conjunctivitis in Argentina, Singapore, Hong Kong and Malaysia (Ophthalmic) before February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top